Valneva SE got a termination notice from the UK Government on its Supply Agreement for its COVID-19 vaccine candidate according to a press release by Valneva on Monday.
- The contract provides HMG with the right to terminate. HMG has alleged that the company is in breach of its obligations under the Supply Agreement.
- Valneva is pushing on with its VLA2001 development plan. Testing for the Company’s pivotal Phase 3 trial, Cov-Compare, is ongoing at Public Health England.
- Recently, Valneva announced that its Phase 3 results are expected to be available early in the 4th quarter and that these results will form part of its rolling submission for conditional approval of VLA2001 with the UK’s Medicines and Healthcare products Regulatory Agency.
- Valneva has worked on the collaboration with HMG including investing significant resources and effort to respond to HMG including investing significant resources and effort to respond to HMG’s requests for variant-derived vaccines.
Valneva is committed to the development of VLA2001 and will increase its efforts with other potential customers to ensure the inactivated vaccine can be used in fighting the COVID-19 pandemic. VLA down -33.03%.